Defects in the gene for the IL-7 receptor (R) a chain are one cause of severe combined immunodeficiency disease (SCID) based on a strict requirement for IL-7 in T lymphoid development and survival. We tested the feasibility and potentially undesirable consequences of IL-7Ra gene transfer as a therapy for this genetic defect. The murine IL-7Ra gene was introduced into IL-7Ra À/À bone marrow progenitors using retrovirus and transplanted into Rag À/À recipient mice. Both ab and gd T cells were reconstituted in thymus and spleen showing proof of principle. B-cell development was also restored in some mice, but their numbers were much lower than in the T-cell compartment. Splenomegaly was observed due to an increase in neutrophils. We showed that hematopoeitic progenitors, after transfection with IL-7Ra, could respond to IL-7 in vitro by a striking production of neutrophils and other myeloid cells. These data indicate that although IL-7 is a critical lymphopoietin, ectopic expression of its receptor on multipotential progenitors can also induce production of myeloid cells, presumably through survival and proliferation signals that are not restricted to lymphoid cells. This supports the stochastic model of progenitor differentiation, in which cytokines give permissive and not instructive signals.
Introduction
IL-7 is a cytokine produced by nonlymphoid cells that is critical for the development and survival of T lymphocytes. 1 In the mouse (but not man) IL-7 is also required for development of B lymphocytes. IL-7 receptor is primarily expressed on cells of the lymphoid lineage and consists of the IL-7Ra chain, which binds IL-7 (and a related cytokine TSLP) with high affinity, and the g c chain, which also serves as part of the receptors for IL-2, -4, -9, -15 and -21. Two tyrosine kinases are associated with the intracellular domains of the a and g c chains, Jak1 and Jak3, respectively.
In man, genetic defects in IL-7Ra, 2,3 g c 4 or Jak3 5 are causes of severe combined immunodeficiency, and knockout mice for each of these genes recapitulates the human disorder. The requirement for IL-7 was first recognized in the development of thymocytes, [6] [7] [8] in which IL-7 serves primarily as a survival factor for proT cells by inducing bcl-2 synthesis 9-11 and repressing Bax activation. 12, 13 IL-7 also promotes some differentiation events in thymocytes, rearrangement of the TCRg locus 14 and selection of CD8 cells. 15 Later it was appreciated that mature T cells after leaving the thymus also require IL-7 for survival in the periphery. 16, 17 There are two approaches for treatment of severe combined immunodeficiency disease (SCID) patients who would otherwise develop severe infections and die within the first year of life. Transplantation of hematopoietic progenitors from a matched donor is one option that has been in use for some time, but is not without risk. 18 More recently, gene therapy has been used to treat g c -deficient SCID patients 19 and was successful in restoring adaptive immunity in nine of 10 patients, making this the first durable cure of a human disease using gene therapy. However, two of 10 patients later developed lymphoma 20 attributed to insertional activation of LMO2, a protooncogene previously implicated in lymphomas. The g c gene may offer a unique risk for insertional activation of an oncogene since therapy with other genes has not been a problem so far, thus it is worthwhile to continue to explore the potential for gene therapy in other defects.
Here we tested the feasibility of correcting human IL7Ra deficiency with gene therapy by testing the effect of retroviral introduction of IL-7Ra into IL-7Ra À/À murine hematopoietic progenitors. We observe a durable reconstitution of T cells demonstrating proof of principle. An unanticipated affect of this gene therapy was an increase in production of neutrophils.
Infected bone marrow cells were transplanted into Rag1 À/À mice and the development of T cells in thymus was evaluated 1 month later by flow cytometry. We chose Rag1 À/À mice as recipients because IL-7R À/À themselves are somewhat 'leaky' in that some, but not all individuals slowly accumulate lymphocytes and we would be less confident that lymphocytes were of donor origin. The total number of thymocytes recovered are shown ( Figure 1a) + cells were restored to normal proportions. Development of thymic gd cells was also restored to a level that varied between individuals, one of the higher individuals is shown (Figure 1c) . These results show that retroviral introduction of IL-7Ra into IL-7Ra À/À bone marrow progenitors was capable of restoring normal thymic development of both ab and gd lineages. The increased percentage of high ab cells shown in Figure 1c was not consistently observed in all transplanted mice. IL-7Ra is normally expressed at a high level in DN cells, downregulated in DP stage, then upregulated again at the SP stages. In these experiments, the retroviral promoter maintained IL-7Ra expression throughout the DP stage; however, no apparent effects of this ectopic expression were seen, such as an increase in the number of DP cells or a skewing of development to the CD8 lineage. Figure 2d ) down to very low ratio. Thus, whereas the T-cell lineage was reconstituted to fairly normal levels in the thymus and periphery in these mice, B-cell reconstitution was less complete as will be discussed.
Reconstitution of splenic lymphoid cells

Expansion of neutrophils in spleen by IL-7Ra transfer
Mice receiving IL-7Ra-transfected progenitors consistently displayed enlargement of the spleen from 1 to 3 months after transfer attributable to an expansion in the number of neutrophils (Figures 3 and 5a) . Thus, analysis by flow cytometry showed that the predominant GFP-positive cells (60%) coexpressed Mac-1 and Gr-1 + (Figure 5a ), markers of mature neutrophils, and this was confirmed by cytological examination ( Figure  5b ). The number of neutrophils in the spleens of normal mice or GFP + neutrophils in irradiated mice receiving . In comparison, transfection of signaling IL-7 receptors resulted in nearly a log increase in splenic neutrophils. Various mutations in the intracellular domain of IL-7Ra have previously been evaluated for function in an IL-7-dependent thymocyte line and in T-cell development 21 and here were compared for their capacity to induce neutrophilia. The functional IL-7 receptors shown in Figure 3 are mWT, mY401F and mdelSer (deletion of amino acids (AA) 359-394), all of which induced neutrophilia. The nonsignaling mutant, mdelBox1 (deletion of AA 272-279) failed to induce neutrophilia as did the vector control. A partial signaling mutant, mY449F, gave about 10% reconstitution of T-cell development (not shown) and also induced a small increase in splenic neutrophils. Thus, enforced expression of functional IL-7 receptors in hematopoietic progenitors not only affected the lymphoid lineage but also greatly enhanced the granulocytic lineage development.
Functional assay of reconstituted T cells
The proliferative capacity of T cells reconstituted by IL-7R gene therapy was tested in vitro. As shown in Figure  4a and b, reconstituted T cells responded vigorously to the T-cell mitogen anti-CD3. Responses of IL-7R-reconstituted T cells were somewhat more robust than those of normal T cells from C57Bl/6 mice. This demonstrates both that the IL-7R gene therapy was successful, and also shows that the presence of unusually large numbers of neutrophils bearing IL-7R did not impair T-cell function, at least by this measure of responsiveness in vitro. However, the absolute numbers of T cells after IL-7R gene therapy were lower than in normal mice ( Mature neutrophils express transfected IL-7R but fail to respond to IL-7 in vitro IL-7 protects T cells from apoptotic cell death and because neutrophils have a short lifespan, one explanation of the effect of transfected IL-7Ra could be due to an extension of their lifespan. We therefore examined whether these neutrophils expressed the transfected receptor and responded to IL-7 in vitro. As shown in Figure 5c , most of the GFP + neutrophils transfected with IL-7Ra expressed the receptor on their surface, whereas neutrophils from vector controls did not. To determine whether IL-7 promoted survival of these IL-7Ra-expressing neutrophils in vitro, we then sorted the Gr- 
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Q Jiang et al cells from the IL-7R group and cultured them with or without IL-7 for 24 h. There was no significant difference in cell numbers undergoing apoptosis between the two groups ( Figure 5d ). This indicates that these mature neutrophils, despite expressing the IL-7Ra chain, were not protected from cell death by IL-7 in vitro. This supports the hypothesis that the accumulation of splenic neutrophils in these mice is not due to effects at the mature neutrophil stage. However, since these experiments were performed in vitro, they do not rule out the possibility that in vivo mature neutrophils could survive longer in response to IL-7.
Enforced expression of IL-7Ra confers IL-7 responsiveness to hematopoietic progenitors in vitro
Having shown that mature neutrophils ectopically expressing IL-7Ra chain failed to respond to IL-7 by increased survival in vitro, we sought an effect on the generation of neutrophils to explain their increase in IL-7Ra-transfected mice. To test this, IL-7Ra À/À bone marrow was enriched for cycling progenitors by injection with 5FU in vivo and harvest 4 days later. Cells were then infected in vitro with IL-7Ra or empty vector (pMIG) retroviral supernatants. After 48 h of culture, Scal-1 + ckit
+ cells were sorted and placed in culture with or without mIL-7. An MTT assay showed that these hematopoietic progenitors transfected with IL-7Ra displayed a dramatic response to IL-7, whereas vector (pMIG) controls showed little or no response (Figure 6a ). After 6 days culture with IL-7, progenitors transfected with IL-7Ra generated Mac1 + Gr-1 + mature neutrophils (Figure 6b ), whereas no cells could be recovered and examined from the other groups. In addition to different stages in neutrophil development, other types of hematopoietic cells were also found in the cytospin slides, including macrophages and megakaryocytes (Figure 6c ). These results demonstrate that, although IL-7R is required for development and survival of lymphoid cells, transfection of IL-7Ra into hematopoietic progenitors confers a survival and proliferative response to IL-7 and generates nonlymphoid cells, especially neutrophils.
Discussion
We show that the lymphoid deficiency in mice lacking IL-7Ra can be treated by introducing this gene into hematopoietic progenitors using retroviral transfection. The T lymphoid compartment was restored, including the major thymic stages and peripheral ab T cells and endured as long as tested (4 months). Restoration of gd T-cell development occurred but the degree varied between individuals. B-cell development was also restored although to lower and more variable numbers. An unanticipated result was nearly a log increase in neutrophils which resulted from the ectopic expression of IL-7Ra on neutrophil progenitors, conferring a response to IL-7 and a greatly increased production of neutrophils.
Genetic deficiency in IL-7Ra is one of the causes of human SCID. 2, 3 Two other SCID genetic defects, g c 22 and adenosine deamidase, 23 have been reversed in humans using retroviral gene therapy similar to that employed in our study. Our findings show proof of principle that this therapy can also restore the lymphoid deficiency in patients with defects in the IL-7Ra gene, which is a lifethreatening condition. However, the unanticipated increase in neutrophil production raises concerns. IL-7 is required for B-cell development in mice, but not humans. B-cell development was rescued in these mice, IL-7Ra is normally downregulated at several developmental and activation stages in thymocytes and mature T cells, and retroviral expression could have functional affects, for example in protecting inappropriate T cells from death. DP cells normally downregulate IL-7Ra and the re-expression is associated with CD8 selection; 15 however, we did not observe a disproportionate increase either in DP or CD8 thymocytes. It remains to be determined whether these DP cells ectopically expressing IL-7Ra are more resistant to death, or whether inappropriate TCR specificities are positively selected in these mice. Memory T cells appear to be selected from activated T cells expressing the highest levels of IL-7Ra, 26 and constitutive expression could also perturb this selection.
It was surprising that IL-7, which is an essential lymphopoietin, could drive myeloid cell production if the IL-7Ra chain was ectopically expressed on hematopoietic progenitors. Perhaps the IL-7 receptor mimicks signaling from a cytokine receptor that is normally involved in myeloid development, such as GCSF receptor. This implies that the myeloid progenitors contain the required apparatus for IL-7 to signal through IL-7Ra, including g c , Jak1 and Jak3. This also implies that downstream effects of the two signaling pathways are interchangeable between the lymphoid and myeloid lineages, presumably the survival and proliferative effects. IL-7 has survival effects on lymphoid cells based on induction of Bcl-2 synthesis 10 and constraint of the death protein Bax to the cytosol 12, 13 and perhaps these events also occur in myelopoiesis. Mcl-1 is another prosurvival member of the Bcl-2 family that was originally found in myeloid cells and contributes to the survival effects of GM-CSF in myelopoiesis. Recently, IL-7 was shown to induce synthesis of Mcl-1 during lymphopoiesis; 27 thus, Mcl-1 could be a common, IL-7-induced mediator of survival between the lymphoid lineage and the myeloid lineage when the latter are artificially endowed with the capacity to respond to IL-7. If IL-7 acted by mimicking GCSF or GM-CSF on myeloid progenitors, it failed to do so in mature neutrophils in vitro, which, despite expressing IL-7Ra, did not respond by increased survival, as do mature neutrophils in response to GCSF or GM-CSF. 28 The observation that IL-7 receptor signals can support myeloid development supports a stochastic model for myeloid differentiation, rather than an instructive model. Thus, in an instructive model, myeloid differentiation would require signals from a 'myeloid factor' like GCSF or GM-CSF, which our results show are not required and can be replaced by a 'lymphoid' factor, IL-7. In a stochastic model, myeloid progenitors are envisioned to develop at random from pluripotent progenitors; these randomly generated myeloid precursors could then generate mature myeloid cells in response to any signal that induced their survival and proliferation, and that appears to be the explanation of the action of IL-7 in the present study. This implies that IL-7 is normally a lymphoid and not a myeloid factor because the former normally express the IL-7 receptor whereas the latter normally do not. There are several reports that ectopic expression of 'lineage-specific' hematopoietic receptors can induce other lineages, including EPOR, 29, 30 CSF-1R, 31 GM-CSF, 32 GCSF, 33, 34 and IL5R. 35 Injection of IL-7 into mice also induces an increase in neutrophils, 36, 37 however this appears to be an indirect effect partly mediated by IL-3 and GM-CSF produced by IL-7-activated T cells (Aiello et al, manuscript in preparation).
The increase in mature neutrophils in these mice resembles a relatively rare condition in man 'chronic neutrophilic leukemia'. This syndrome is distinct from the more common 'chronic myeloid leukemia' which is an increase in immature myeloid cells (not mature neutrophils as seen here), and is also distinguishable by the presence of the Philadelphia chromosome. From our study, the increase in neutrophils induced by ectopic expression of IL-7Ra could present problems in patients, and could even pose an increased risk for myeloid leukemia, although thus far we have not observed leukemia in a small cohort of mice observed for 4 months. To reduce the risk of inducing the neutrophilia we observed here, it might be possible to restrict the expression of the IL-7Ra transgene using a promoter that is more limited in expression, such as a lymphoidspecific promoter or the IL-7Ra promoter itself.
A risk of retroviral gene therapy is the insertional activation of oncogenes. This occurred in the T-cell leukemias that developed in three of 10 patients treated for g c deficiency in France, 20 in two of which the LMO2 gene was activated by vector insertion. It might seem that the same leukemia risk would occur in treating IL7Ra-deficient patients with the IL-7Ra gene since these patients have, before treatment, a very similar phenotype to those with g c deficiency. However, it has recently been argued that g c gene therapy presents a unique risk for leukemia because the retroviral promoter drives the expression of g c constitutively and this may in turn drive excessive cell division and increase the risk of secondary mutation in addition to insertional activation of an oncogene. 38 Thus, therapy with other genes has not induced cancer in mice or man, perhaps because their constitutive expression does not induce excessive cell division, and hopefully IL-7Ra will fall into this category.
Materials and methods
Mice
Normal C57/B6 mice were purchased from Charles River (Frederick, MD, USA). IL-7Ra À/À mice (B6.129S7-IL-7 rtm1lm ) and Rag1 À/À mice were purchased from the Jackson Laboratory (Bar Harbor, MN, USA) and maintained by homozygous breeding at the NCI-FCRDC animal facility.
Cell lines
The retroviral package cell line phoenix-Eco 39 was maintained in DMEM (Mediatech Inc.), supplemented with 10% FBS (Hyclone) and 100 U of penicillin/ml and 100 mg of streptomycin (Mediatech Inc.) per ml.
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Retroviral plasmid construction and bone marrow cell infection
Full-length murine IL-7Ra was cloned into the pMIG vector, designated 'IL-7R', which also produces GFP (as a separate protein). Different mutations were introduced into the IL-7 receptor intracellular domain using PCR strategies. All mutated genes were cloned into pMIG vector and were verified by DNA sequencing. 21 Plasmids were transiently transfected into the phoenix-Eco packaging cells and the supernatants were collected.
Cycling bone marrow progenitors were enriched by injecting ILRa À/À mice with 5FU (150 mg/kg) (Schein pharmaceuticals) in DPBS 4 days prior to harvest of bone marrow from tibiafibula and femur. Bone marrow cells were cultured in X-vivo 10 medium (Bio Whittaker) supplemented with 5% FBS, murine SCF (100 ng/ml), murine IL6 (50 ng/ml) and flt-3 ligand (100 ng/ml) (Peprotech). After 48 h, bone marrow cells were infected on RetroNectin (TaKaRa)-coated plates overnight with different retroviral supernatant from the packaging line and the infection was repeated after 72 h.
On the 4th day of culture, 2 Â 10 6 infected bone marrow cells were injected intravenously into Rag1 À/À recipients previously treated with 3 Gy whole body irradiation.
Flow cytometry
At 4 weeks after bone marrow reconstitution, mice were killed and thymus and spleen cell suspensions were stained with PE-conjugated anti-CD4, cychrome-conjugated anti-CD8, PE-conjugated anti-TCR-gd, Cychromeconjugated anti-TCR-b, PE-conjugated anti-IgM, Cychrome-conjugated anti-B220, PE-conjugated antiMac-1, APC-conjugated anti-Gr-1 antibodies (Pharmingen) or PE-cy5-conjugated anti-IL-7Ra (Bioscience) antibody. Stained cells were analyzed or sorted on a FACScan flow cytometer.
In vitro proliferation assay
Spleen cells, either unfractionated or purified CD4 + or CD8 + cells, were cultured in anti-CD3 antibody (BD Pharmingin) coated 96-well plate (10 mg/ml, 41C, overnight, washed once with PBS just before use). Cells were pulsed with 1 mCi [ 3 H]thymidine (6.7 Ci/mmol, PerkinElmer Life Sciences Inc.) per well overnight and harvested onto a glass-fiber filter paper (Tomtech Harvester 96; Tomtech, Inc. and Filtermat A; Wallac Oy). Filters were dried overnight and counted using a 1205 Betaplate liquid scintillation counter (LKB Wallac, Perkin-Elmer).
Ex vivo culture of neutrophils GFP + Gr-1 + cells (including mature and immature neutrophils) were sorted from spleens of mice a month after receiving IL-7R À/À progenitors transfected with IL-7Ra. Neutrophils were cultured with or without mIL-7 (Pepro Tech) for 24 h, then analyzed for apoptotic cells using an AnnexinV-PE apoptosis detection kit (BD Pharmingen) and flow cytometry.
In vitro generation of neutrophils from bone marrow progenitors
Cycling bone marrow cells were enriched from IL-7Ra À/À as above and cells were infected with IL-7Ra or control vector (pMIG) retroviruses. Progenitors were then enriched by sorting positive cells stained with PEconjugated Scal-1 and APC-conjugated c-kit. Cells were then cultured with or without mIL-7 in 100 ml or 3 ml cultures. After 3 days, 8 ml of MTT/well (5 mg/ml, Sigma) was added per 100 ml culture and incubated for 4 h. Then, 100 ml of solubilization solution (Promega) was added and incubated overnight at 371C. Plates were read by spectrophotometer at wavelength 570 and 620 nm. From 3 ml cultures, cells were recovered and stained with PE-conjugated anti-Mac-1 and APC-conjugated anti-Gr-1 antibodies and analyzed by flow cytometry. Recovered cells were also prepared by cytospin onto slides and stained with Hama 3 staining set (Biochemical Sciences Inc.).
